SKLB-178

N/A

Report date: 2026/05/08 20:02:52
NME

Base Information

Drug NameSKLB-178
Drug Alias NameSKLB-178
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVascular endothelial growth factor receptor 2 inhibitorsTyrosine-protein kinase SRC inhibitorsEGFR T790M inhibitors +[5] 
TargetsEpidermal growth factor receptor erbB1Vascular endothelial growth factor receptor 2Tyrosine-protein kinase SRC +[5] 
Therapy Area/IndicationsCarcinoma, Non-Small-Cell Lung
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesSichuan University
China Registration ClassN/A

Develop Information

Active CompaniesSichuan University
Inactive CompaniesN/A
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A